Future SUPAC Guidances Will Be "Dosage-Independent" - FDA's Sager
This article was originally published in The Tan Sheet
Executive Summary
Future guidances following the Scale-Up & Post-Approval Changes model likely will not focus on individual dosage forms, FDA Office of Pharmaceutical Science Quality Implementation Associate Director Nancy Sager told the American Association of Pharmaceutical Science March 16 in Crystal City, Va.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning